Comparison of Nebulized 3% Hypertonic Saline and Ipratropium Bromide in the Treatment of Children With Bronchiolitis

Tayyaba Nazir1, Israr Liaquat1, Saad Junaid1, Fatima Riaz1
1Department of Pediatrics, Holy Family Hospital, Rawalpindi, Pakistan
DOI: https://doi.org/10.70517/revcc2624215
Published: 19/11/2026
: Tayyaba Nazir, Israr Liaquat, Saad Junaid, Fatima Riaz. Comparison of Nebulized 3% Hypertonic Saline and Ipratropium Bromide in the Treatment of Children With Bronchiolitis. Revista Cultura Científica, 2026 Issue 24. pg. 2681-2691.

Abstract

Bronchiolitis is a common acute lower respiratory tract infection in infants and young children that can cause substantial respiratory distress and require hospital admission. This study aimed to compare nebulized 3% hypertonic saline with nebulized ipratropium bromide regarding respiratory distress, oxygen saturation, and hospital outcomes among children aged 2–24 months with acute bronchiolitis. A randomized controlled trial was conducted in the Department of Pediatrics, Holy Family Hospital, Rawalpindi, Pakistan, from June to September 2026. One hundred children with physician-diagnosed bronchiolitis were enrolled consecutively and randomly allocated by lottery to receive nebulized 3% hypertonic saline (n=50) or ipratropium bromide (n=50). The groups were comparable in recorded baseline characteristics. Mean baseline Respiratory Distress Assessment Instrument (RDAI) scores were 8.6 ± 1.8 and 8.5 ± 1.9, respectively, while baseline oxygen saturation (SpO2) was 91.4 ± 2.5% and 91.2 ± 2.4%. At 24 hours, mean RDAI scores were 3.7 ± 1.5 with hypertonic saline and 5.0 ± 1.6 with ipratropium; at 48 hours, the corresponding scores were 2.6 ± 1.3 and 3.8 ± 1.4 (both p < 0.001). SpO2 at 24 hours was 96.0 ± 1.4% and 94.9 ± 1.7%, respectively (p < 0.001). Mean hospital stay was 2.63 ± 1.12 days versus 3.82 ± 1.06 days (p < 0.001); discharge within 72 hours occurred in 90.0% versus 74.0% of children (reported p=0.044). Within this trial, nebulized 3% hypertonic saline was associated with greater short-term improvement in respiratory distress and oxygen saturation, a shorter hospital stay, and more frequent discharge within 72 hours than nebulized ipratropium bromide. These findings require independent confirmation and should be interpreted alongside established bronchiolitis management guidelines.

Keywords: Acute bronchiolitis; Hypertonic saline; Ipratropium bromide; Respiratory Distress Assessment Instrument; Oxygen saturation; Randomized controlled trial

Abstract

Bronchiolitis is a common acute lower respiratory tract infection in infants and young children that can cause substantial respiratory distress and require hospital admission. This study aimed to compare nebulized 3% hypertonic saline with nebulized ipratropium bromide regarding respiratory distress, oxygen saturation, and hospital outcomes among children aged 2–24 months with acute bronchiolitis. A randomized controlled trial was conducted in the Department of Pediatrics, Holy Family Hospital, Rawalpindi, Pakistan, from June to September 2026. One hundred children with physician-diagnosed bronchiolitis were enrolled consecutively and randomly allocated by lottery to receive nebulized 3% hypertonic saline (n=50) or ipratropium bromide (n=50). The groups were comparable in recorded baseline characteristics. Mean baseline Respiratory Distress Assessment Instrument (RDAI) scores were 8.6 ± 1.8 and 8.5 ± 1.9, respectively, while baseline oxygen saturation (SpO2) was 91.4 ± 2.5% and 91.2 ± 2.4%. At 24 hours, mean RDAI scores were 3.7 ± 1.5 with hypertonic saline and 5.0 ± 1.6 with ipratropium; at 48 hours, the corresponding scores were 2.6 ± 1.3 and 3.8 ± 1.4 (both p < 0.001). SpO2 at 24 hours was 96.0 ± 1.4% and 94.9 ± 1.7%, respectively (p < 0.001). Mean hospital stay was 2.63 ± 1.12 days versus 3.82 ± 1.06 days (p < 0.001); discharge within 72 hours occurred in 90.0% versus 74.0% of children (reported p=0.044). Within this trial, nebulized 3% hypertonic saline was associated with greater short-term improvement in respiratory distress and oxygen saturation, a shorter hospital stay, and more frequent discharge within 72 hours than nebulized ipratropium bromide. These findings require independent confirmation and should be interpreted alongside established bronchiolitis management guidelines.

Keywords: Acute bronchiolitis; Hypertonic saline; Ipratropium bromide; Respiratory Distress Assessment Instrument; Oxygen saturation; Randomized controlled trial

References

  1. National Institute for Health and Care Excellence. “Bronchiolitis in Children: Diagnosis and Management.” NICE Guideline NG9, 2015, updated 2021. https://www.nice.org.uk/guidance/ng9.

  2. Ralston, Shawn L., et al. “Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis.” Pediatrics, vol. 134, no. 5, 2014, pp. e1474–e1502. https://doi.org/10.1542/peds.2014-2742.

  3. Zhang, Linjie, et al. “Nebulised Hypertonic Saline Solution for Acute Bronchiolitis in Infants.” Cochrane Database of Systematic Reviews, no. 4, 2023, CD006458. https://doi.org/10.1002/14651858.CD006458.pub5.

  4. Yu, Jin-Feng, et al. “3% Nebulized Hypertonic Saline versus Normal Saline for Infants with Acute Bronchiolitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Medicine, vol. 101, no. 43, 2022, e31270. https://doi.org/10.1097/MD.0000000000031270.

  5. Beal, Gaëlle, et al. “Nebulized Hypertonic Saline 3% for 1 versus 3 Days in Hospitalized Bronchiolitis: A Blinded Non-Inferiority Randomized Controlled Trial.” BMC Pediatrics, vol. 19, 2019, article 417. https://doi.org/10.1186/s12887-019-1804-0.

  6. Jaquet-Pilloud, Raphaelle, et al. “Nebulised Hypertonic Saline in Moderate-to-Severe Bronchiolitis: A Randomised Clinical Trial.” Archives of Disease in Childhood, vol. 105, no. 3, 2020, pp. 236–240. https://doi.org/10.1136/archdischild-2019-317160.

  7. Henry, R. L., A. D. Milner, and G. M. Stokes. “Ineffectiveness of Ipratropium Bromide in Acute Bronchiolitis.” Archives of Disease in Childhood, vol. 58, no. 11, 1983, pp. 925–926. https://doi.org/10.1136/adc.58.11.925.

  8. Wang, E. E., et al. “Bronchodilators for Treatment of Mild Bronchiolitis: A Factorial Randomised Trial.” Archives of Disease in Childhood, vol. 67, no. 3, 1992, pp. 289–293. https://doi.org/10.1136/adc.67.3.289.

  9. Naveed, Hina, et al. “Comparison of Nebulised 3% Hypertonic Saline with Ipratropium Bromide in Treatment of Children with Bronchiolitis: A Randomized Control Trial.” Annals of Medicine and Surgery, vol. 85, no. 11, 2023, pp. 5484–5490. https://doi.org/10.1097/MS9.0000000000001174.

  10. Shahid, Sidra, Asif Javeed, and Saba Wamiq. “Outcome of Hypertonic Saline versus Normal Saline in Children with Acute Bronchiolitis.” Pakistan Journal of Medical & Health Sciences, vol. 16, no. 9, 2022, p. 278. https://doi.org/10.53350/pjmhs22169278.

  11. Pandit, P., et al. “Efficacy of Nebulized Hypertonic Saline (3%) versus Normal Saline and Salbutamol in Treating Acute Bronchiolitis in a Tertiary Hospital: A Randomized Controlled Trial.” Mymensingh Medical Journal, vol. 31, no. 2, 2022, pp. 295–303. https://pubmed.ncbi.nlm.nih.gov/35383741/.

  12. Rajvanshi, Nikhil, et al. “Assessing Bronchiolitis Severity: A Comparative Analysis of Two Commonly Used Clinical Scoring Systems.” European Journal of Pediatrics, vol. 184, no. 2, 2025, article 167. https://doi.org/10.1007/s00431-025-06000-3.

Tayyaba Nazir
Department of Pediatrics, Holy Family Hospital, Rawalpindi, Pakistan
Israr Liaquat
Department of Pediatrics, Holy Family Hospital, Rawalpindi, Pakistan
Saad Junaid
Department of Pediatrics, Holy Family Hospital, Rawalpindi, Pakistan
Fatima Riaz
Department of Pediatrics, Holy Family Hospital, Rawalpindi, Pakistan

How to cite:

Tayyaba Nazir, Israr Liaquat, Saad Junaid, Fatima Riaz. Comparison of Nebulized 3% Hypertonic Saline and Ipratropium Bromide in the Treatment of Children With Bronchiolitis. Revista Cultura Científica, 2026 Issue 24. pg. 2681-2691.

Publication History

Copyright © 2026, Tayyaba Nazir, Israr Liaquat, Saad Junaid, Fatima Riaz. Published by Revista Cultura Científica. This article is published as open access under the Creative Commons Attribution 4.0 International (CC BY 4.0) license (http://creativecommons.org/licenses/by/4.0/).

Browse Advance Search